Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO)

CUSIP: 98422T100

Q2 2023 13F Holders as of 30 Jun 2023

Security type / class
Equity / Common Stock, par value $0.0001 per share
Total 13F shares
16,002,286
Total 13F value
$41,925,598
Holder snapshot 6 signals
Share change
-69,771
SEC-reported price per share
$2.62
Number of holders
32
Value change
-$192,245
Number of buys
5
Number of sells
7
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
6,426,426

Security key

98422T100

Report period

Q2 2023

Institutions

32

Top holders

10

XLO full security history Ownership snapshot Full 13F holder table Newer quarter: Q3 2023 Previous quarter: Q1 2023 Xilio Therapeutics, Inc. SEC filings Xilio Therapeutics, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Bain Capital Life Science...
Disclosed value leader
Bain Capital Life Science...
Comparable rows
15/15
Latest evidence
31 Mar 2023
13F 3/4/5 Lead comparable stake: 44% Showing 1-6 of 15 holder rows.

Quick read

Bain Capital Life Sciences Investors, LLC leads the comparable SEC ownership view at 44%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Bain Capital Life Sciences Investors, LLC's linked filing trail.
Comparable ownership Top 5
Bain Capital Life Sciences Invest... 44%
Atlas Venture Life Science Adviso... 43%
Octagon Capital Advisors LP 38%
FMR LLC 30%
RiverVest Venture Management LLC 22%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Bain Capital Life Sciences Investors, LLC
13F 3/4/5
Company · 10%+ Owner
13F 3/4/5
44%
$8,893,000
2,805,413 shares
 — 31 Mar 2023
Atlas Venture Life Science Advisors, LLC
13F
Company
13F
43%
$8,747,120
2,759,344 shares
 — 31 Mar 2023
Octagon Capital Advisors LP
13F
Company
13F
38%
$7,687,250
2,425,000 shares
 — 31 Mar 2023
FMR LLC
13F 3/4/5
Company · Other*
13F 3/4/5
30%
$6,066,394
1,907,671 shares
 — 31 Mar 2023
RiverVest Venture Management LLC
13F
Company
13F
22%
$4,569,377
1,441,444 shares
 — 31 Mar 2023
Rock Springs Capital Management LP
13F 3/4/5
Company · 10%+ Owner
13F 3/4/5
22%
$4,567,206
1,440,759 shares
 — 31 Mar 2023
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2023

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
32
Shares
16,002,286
Rows available
32
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2023 vs Q1 2023 Across Filers

Q1 2023 holders
32
Q2 2023 holders
32
Holder diff
0
Investor Q1 2023 Shares Q2 2023 Shares Share Diff Share Chg % Q1 2023 value Q2 2023 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .